183 related articles for article (PubMed ID: 24535830)
1. Drug-drug interaction and doping, part 2: an in vitro study on the effect of non-prohibited drugs on the phase I metabolic profile of stanozolol.
Mazzarino M; de la Torre X; Fiacco I; Botrè F
Drug Test Anal; 2014 Oct; 6(10):969-77. PubMed ID: 24535830
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interaction and doping, part 1: an in vitro study on the effect of non-prohibited drugs on the phase I metabolic profile of toremifene.
Mazzarino M; de la Torre X; Fiacco I; Palermo A; Botrè F
Drug Test Anal; 2014 May; 6(5):482-91. PubMed ID: 24431005
[TBL] [Abstract][Full Text] [Related]
3. Drug-drug interaction and doping: Effect of non-prohibited drugs on the urinary excretion profile of methandienone.
Mazzarino M; Khevenhüller-Metsch FL; Fiacco I; Parr MK; de la Torre X; Botrè F
Drug Test Anal; 2018 Oct; 10(10):1554-1565. PubMed ID: 29766657
[TBL] [Abstract][Full Text] [Related]
4. The application of in vitro technologies to study the metabolism of the androgenic/anabolic steroid stanozolol in the equine.
Scarth JP; Spencer HA; Hudson SC; Teale P; Gray BP; Hillyer LL
Steroids; 2010 Jan; 75(1):57-69. PubMed ID: 19854209
[TBL] [Abstract][Full Text] [Related]
5. Effect of non-prohibited drugs on the phase II metabolic profile of morphine. An in vitro investigation for doping control purposes.
Ambrosio G; de la Torre X; Mazzarino M; Parr MK; Botrè F
Drug Test Anal; 2018 Jun; 10(6):984-994. PubMed ID: 29172026
[TBL] [Abstract][Full Text] [Related]
6. Detection of stanozolol O- and N-sulfate metabolites and their evaluation as additional markers in doping control.
Balcells G; Matabosch X; Ventura R
Drug Test Anal; 2017 Jul; 9(7):1001-1010. PubMed ID: 27714936
[TBL] [Abstract][Full Text] [Related]
7. A novel HPLC-MRM strategy to discover unknown and long-term metabolites of stanozolol for expanding analytical possibilities in doping-control.
Wang Z; Zhou X; Liu X; Dong Y; Zhang J
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jan; 1040():250-259. PubMed ID: 27842983
[TBL] [Abstract][Full Text] [Related]
8. Investigations into the concentration and metabolite profiles of stanozolol and LGD-4033 in blood plasma and seminal fluid using liquid chromatography high-resolution mass spectrometry.
Breuer J; Thomas A; Delahaut P; Schänzer W; Geyer H; Thevis M
Anal Bioanal Chem; 2023 Feb; 415(4):669-681. PubMed ID: 36441233
[TBL] [Abstract][Full Text] [Related]
9. Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry.
Pozo OJ; Van Eenoo P; Deventer K; Lootens L; Grimalt S; Sancho JV; Hernández F; Meuleman P; Leroux-Roels G; Delbeke FT
Steroids; 2009 Oct; 74(10-11):837-52. PubMed ID: 19464304
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of the effects of anti-fungals, benzodiazepines and non-steroidal anti-inflammatory drugs on the glucuronidation of 19-norandrosterone: implications on doping control analysis.
Palermo A; Alessi B; Botrè F; de la Torre X; Fiacco I; Mazzarino M
Drug Test Anal; 2016 Sep; 8(9):930-9. PubMed ID: 26480899
[TBL] [Abstract][Full Text] [Related]
11. Application of FAIMS to anabolic androgenic steroids in sport drug testing.
Guddat S; Thevis M; Kapron J; Thomas A; Schänzer W
Drug Test Anal; 2009 Nov; 1(11-12):545-53. PubMed ID: 20355171
[TBL] [Abstract][Full Text] [Related]
12. Expanding analytical possibilities concerning the detection of stanozolol misuse by means of high resolution/high accuracy mass spectrometric detection of stanozolol glucuronides in human sports drug testing.
Schänzer W; Guddat S; Thomas A; Opfermann G; Geyer H; Thevis M
Drug Test Anal; 2013; 5(11-12):810-8. PubMed ID: 23873860
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and excretion of anabolic steroids in doping control--new steroids and new insights.
Van Eenoo P; Delbeke FT
J Steroid Biochem Mol Biol; 2006 Nov; 101(4-5):161-78. PubMed ID: 17000101
[TBL] [Abstract][Full Text] [Related]
14. Stanozolol-N-glucuronide metabolites in human urine samples as suitable targets in terms of routine anti-doping analysis.
Göschl L; Gmeiner G; Gärtner P; Stadler G; Enev V; Thevis M; Schänzer W; Guddat S; Forsdahl G
Drug Test Anal; 2021 Sep; 13(9):1668-1677. PubMed ID: 34089570
[TBL] [Abstract][Full Text] [Related]
15. Detection of mono-hydroxylated metabolites of stanozolol by HPLC-ESI (+) MS/MS in Indian sports persons.
Ahi S; Beotra A; Jain S
Drug Test Anal; 2009 Nov; 1(11-12):538-44. PubMed ID: 20355170
[TBL] [Abstract][Full Text] [Related]
16. Organ-on-a-chip: Determine feasibility of a human liver microphysiological model to assess long-term steroid metabolites in sports drug testing.
Görgens C; Ramme AP; Guddat S; Schrader Y; Winter A; Dehne EM; Horland R; Thevis M
Drug Test Anal; 2021 Nov; 13(11-12):1921-1928. PubMed ID: 34505743
[TBL] [Abstract][Full Text] [Related]
17. Use of in vitro technologies to study phase II conjugation in equine sports drug surveillance.
Taylor P; Scarth JP; Hillyer LL
Bioanalysis; 2010 Dec; 2(12):1971-88. PubMed ID: 21110741
[TBL] [Abstract][Full Text] [Related]
18. Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review.
Gosetti F; Mazzucco E; Gennaro MC; Marengo E
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 927():22-36. PubMed ID: 23317577
[TBL] [Abstract][Full Text] [Related]
19. Sports drug testing using complementary matrices: Advantages and limitations.
Thevis M; Geyer H; Tretzel L; Schänzer W
J Pharm Biomed Anal; 2016 Oct; 130():220-230. PubMed ID: 27040951
[TBL] [Abstract][Full Text] [Related]
20. The Athlete Biological Passport: an integral element of innovative strategies in antidoping.
Vernec AR
Br J Sports Med; 2014 May; 48(10):817-9. PubMed ID: 24659508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
